Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment.

ABSTRACT:

SUBMITTER: Lv J 

PROVIDER: S-EPMC8152428 | biostudies-literature | 2021 May-Jun

REPOSITORIES: biostudies-literature